{"url_path":"/sec/kblb/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1413119/0001493152-26-023130-index.html","accession_number":"0001493152-26-023130","cik":"0001413119","ticker":"KBLB","issuer_name":"Kraig Biocraft Laboratories, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1413119/0001493152-26-023130-index.html","primary_entity_key":"0001413119","primary_entity_name":"Kraig Biocraft Laboratories, Inc."},"word_count":259,"has_tables":true,"body_markdown":"**Item\n2. Unregistered Sales of Equity Securities and Use of Proceeds**\n\n \n\nInformation\nregarding any equity securities we have sold during the period covered by this Report that were not registered under the Securities Act\nof 1933, as amended is set forth below. Each such transaction was exempt from the registration requirements of the Securities Act by\nvirtue of Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D promulgated by the SEC, unless otherwise noted. Unless stated\notherwise: (i) the securities were offered and sold only to accredited investors; (ii) there was no general solicitation or general advertising\nrelated to the offerings; (iii) each of the persons who received these unregistered securities had knowledge and experience in financial\nand business matters which allowed them to evaluate the merits and risk of the receipt of these securities, and that they were knowledgeable\nabout our operations and financial condition; (iv) no underwriter participated in, nor did we pay any commissions or fees to any underwriter\nin connection with the transactions; and, (v) each certificate issued for these unregistered securities contained a legend stating that\nthe securities have not been registered under the Securities Act and setting forth the restrictions on the transferability and the sale\nof the securities.\n\n \n\nOn\nJanuary 15, 2026, the Company issued 2,500,000 Common Stock warrants under its employee stock option plan to an employee with an exercise\nprice of $0.0825.\n\n \n\nOn\nApril 30, 2026, the Company issued 5,959,847 shares of Common Stock to an employee in exchange for the cashless exercise of 6,000,000\nwarrants ."}